Kun Zhao

Kun Zhao

Auto-generated profile, based on publicly available information

Kun Zhao

School of Artificial Intelligence, Beijing University of Posts and Telecommunications, Beijing, China

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2020 in Science Bulletin
Verified
Journal Article
Open access
KZKun Zhao
Kun Zhao
YDYanhui Ding
Yanhui Ding
YHYing Han
Ying Han
YFYong Fan
Yong Fan
AAAaron F. Alexander-Bloch
Aaron F. Alexander-Bloch
YLYong Liu
Yong Liu
Hippocampal morphological change is one of the main hallmarks of Alzheimer's disease (AD). However, whether hippocampal radiomic features are robust as predictors of progression from mild cognitive impairment (MCI) to AD dementia and whether these features provide any neurobiological foundation remains unclear. The primary aim of this study was to verify whether hippocampal radiomic features can serve as robust magnetic resonance imaging (MRI) markers for AD. Multivariate classifier-based support vector machine (SVM) analysis provided individual-level predictions for distinguishing AD patients (n = 261) from normal controls (NCs; n = 231) with an accuracy of 88.21% and intersite cross-validation. Further analyses of a large, independent the Alzheimer's Disease Neuroimaging Initiative (ADNI) dataset (n = 1228) reinforced these findings. In MCI groups, a systemic analysis demonstrated that the identified features were significantly associated with clinical features (e.g., apolipoprotein E (APOE) genotype, polygenic risk scores, cerebrospinal fluid (CSF) Aβ, CSF Tau), and longitudinal changes in cognition ability; more importantly, the radiomic features had a consistently altered pattern with changes in the MMSE scores over 5 years of follow-up. These comprehensive results suggest that hippocampal radiomic features can serve as robust biomarkers for clinical application in AD/MCI, and further provide evidence for predicting whether an MCI subject would convert to AD based on the radiomics of the hippocampus. The results of this study are expected to have a substantial impact on the early diagnosis of AD/MCI.

25 September 2018 in Frontiers in Aging Neuroscience
Verified
Journal Article
Open access
PDF file
FFFeng Feng
Feng Feng
PWPan Wang
Pan Wang
KZKun Zhao
Kun Zhao
BZBo Zhou
Bo Zhou
HYHongxiang Yao
Hongxiang Yao
YLYong Liu
Yong Liu
Alzheimer’s disease (AD) is characterized by progressive dementia, especially in episodic memory, and amnestic mild cognitive impairment (aMCI) is associated with a high risk of developing AD. Hippocampal atrophy/shape changes are believed to be the most robust magnetic resonance imaging (MRI) markers for AD and aMCI. Radiomics, a method of texture analysis, can quantitatively examine a large set of features and has previously been successfully applied to evaluate imaging biomarkers for AD. To test whether radiomic features in the hippocampus can be employed for early classification of AD and aMCI, 1692 features from the caudal and head parts of the bilateral hippocampus were extracted from 38 AD patients, 33 aMCI patients and 45 normal controls (NCs). One way analysis of variance (ANOVA) showed that 111 features exhibited statistically significant group differences (P < 0.01, Bonferroni corrected). Among these features, 98 were significantly correlated with Mini-Mental State Examination (MMSE) scores in AD and aMCI subjects (P < 0.01). The support vector machine (SVM) model demonstrated that radiomic features allowed us to distinguish AD from NC with an accuracy of 86.75% (specificity = 88.89% and sensitivity = 84.21%) and an area under curve (AUC) of 0.93. In conclusion, these findings provide evidence showing that radiomic features are beneficial in detecting early cognitive decline, and SVM classification analysis provides encouraging evidence for using hippocampal radiomic features as a potential biomarker for clinical applications in AD.

9 June 2020 in Advanced Science
Verified
Journal Article
Open access
PDF file
DJDan Jin
Dan Jin
BZBo Zhou
Bo Zhou
YHYing Han
Ying Han
JRJiaji Ren
Jiaji Ren
THTong Han
Tong Han
YLYong Liu
Yong Liu
Precision medicine for Alzheimer's disease (AD) necessitates the development of personalized, reproducible, and neuroscientifically interpretable biomarkers, yet despite remarkable advances, few such biomarkers are available. Also, a comprehensive evaluation of the neurobiological basis and generalizability of the end‐to‐end machine learning system should be given the highest priority. For this reason, a deep learning model (3D attention network, 3DAN) that can simultaneously capture candidate imaging biomarkers with an attention mechanism module and advance the diagnosis of AD based on structural magnetic resonance imaging is proposed. The generalizability and reproducibility are evaluated using cross‐validation on in‐house, multicenter (n = 716), and public (n = 1116) databases with an accuracy up to 92%. Significant associations between the classification output and clinical characteristics of AD and mild cognitive impairment (MCI, a middle stage of dementia) groups provide solid neurobiological support for the 3DAN model. The effectiveness of the 3DAN model is further validated by its good performance in predicting the MCI subjects who progress to AD with an accuracy of 72%. Collectively, the findings highlight the potential for structural brain imaging to provide a generalizable, and neuroscientifically interpretable imaging biomarker that can support clinicians in the early diagnosis of AD.

1 April 2019
Verified
Conference Paper
Closed access
DJDan Jin
Dan Jin
JXJian Xu
Jian Xu
KZKun Zhao
Kun Zhao
FHFangzhou Hu
Fangzhou Hu
ZYZhengyi Yang
Zhengyi Yang
YLYong Liu
Yong Liu

2 July 2019 in IEEE Access
Verified
Journal Article
Open access
ZLZhuoran Li
Zhuoran Li
HDHuichuan Duan
Huichuan Duan
KZKun Zhao
Kun Zhao
YDYanhui Ding
Yanhui Ding
Radiomics is a quantitative method to extract medical features that can extend to details that are invisible to human eyes. Studies have suggested that radiomics of the hippocampus is a potential imaging biomarker for several diseases, including Alzheimer’s disease, mild cognitive impairment, and multiple sclerosis. This study investigates the test-retest reproducibility of radiomics features of the hippocampus. For this purpose, the intra-class correlation coefficient (ICC) and overall concordance correlation coefficient (OCCC) of the radiomics features of the hippocampus were well studied in four datasets consisting of 15, 19, 23, and 3 subjects who were scanned three, two, four, and forty times, respectively. The results highlight that the hippocampal texture features are the most repeatable, and that texture features are a possible neuroimaging biomarker for clinical studies.

22 April 2021 in Cerebral Cortex
Verified
Journal Article
Open access
PDF file
YDYanhui Ding
Yanhui Ding
KZKun Zhao
Kun Zhao
TCTongtong Che
Tongtong Che
KDKai Du
Kai Du
HSHongzan Sun
Hongzan Sun
AIAlzheimer’s Disease Neuroimaging Initiative
Alzheimer’s Disease Neuroimaging Initiative
Growing evidence indicates that amyloid-beta (Aβ) accumulation is one of the most common neurobiological biomarkers in Alzheimer’s disease (AD). The primary aim of this study was to explore whether the radiomic features of Aβ positron emission tomography (PET) images are used as predictors and provide a neurobiological foundation for AD. The radiomics features of Aβ PET imaging of each brain region of the Brainnetome Atlas were computed for classification and prediction using a support vector machine model. The results showed that the area under the receiver operating characteristic curve (AUC) was 0.93 for distinguishing AD (N = 291) from normal control (NC; N = 334). Additionally, the AUC was 0.83 for the prediction of mild cognitive impairment (MCI) converting (N = 88) (vs. no conversion, N = 100) to AD. In the MCI and AD groups, the systemic analysis demonstrated that the classification outputs were significantly associated with clinical measures (apolipoprotein E genotype, polygenic risk scores, polygenic hazard scores, cerebrospinal fluid Aβ, and Tau, cognitive ability score, the conversion time for progressive MCI subjects and cognitive changes). These findings provide evidence that the radiomic features of Aβ PET images can serve as new biomarkers for clinical applications in AD/MCI, further providing evidence for predicting whether MCI subjects will convert to AD.